Understanding the clinical presentation and underlying pathology of Stargardt disease is crucial for identifying patients as well as developing and offering effective treatments. Ongoing research is making strides toward potential therapeutic interventions that could alter the course of the disease.
Options empower patients and providers to decrease treatment burden.
A report from the 16th European Neuro-Ophthalmology Society Meeting held in The Netherlands. Find out more with The Ophthalmologist
Epioxa is a next-generation corneal cross-linking iLink therapy for the treatment of keratoconus.
Enhancing durability and reducing treatment burden.
Investigators conducted a retrospective clinical audit to determine why patients do not adhere to the guidelines among about 9,000 patients in a practice.
Purpose To evaluate the effects of ocular residual astigmatism (ORA) on refractive outcomes for patients with astigmatism after keratorefractive lenticule extraction (KLEx) and to identify…
Wills Eye Resident Series : A patient presents with decreased vision after an injury , p. 62 medicare Q & A 2024 Reimbursement Update Wills…
Purpose: To evaluate for an association between systemic hypertension and intravitreal bevacizumab (IVB) for retinopathy of prematurity (ROP) treatment, due to a 2020 case report…
This economic evaluation study estimates the economic burden of late-stage age-related macular degeneration in 3 countries.
